A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Plaque Psoriasis

Interventions

DRUG

ASC50 tablets or matching placebo

Drug: ASC50 administered orally Drug: Placebo administered orally

Trial Locations (1)

RECRUITING

Ascletis Clinical Site, Miami

All Listed Sponsors

lead

Ascletis Pharma (China) Co., Limited

INDUSTRY